BUND FINANCE › Stocks › LLY
Eli Lilly and Company (LLY)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 19, 2026, 4:02 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +7.43% above its 50-day average.
- It is +21.17% above its 200-day average (long-term uptrend).
- It sits at 80% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$28.3B | US$28.5B | US$34.1B | US$45.0B | US$65.2B |
| Net income | US$5.6B | US$6.2B | US$5.2B | US$10.6B | US$20.6B |
| EPS (diluted) | 6.12 | 6.90 | 5.80 | 11.71 | 22.95 |
| Gross margin | 74.2% | 76.8% | 79.3% | 81.3% | 83.0% |
| Operating margin | 22.5% | 25.0% | 31.6% | 37.8% | 45.6% |
| Net margin | 19.7% | 21.9% | 15.4% | 23.5% | 31.7% |
| Free cash flow | US$5.4B | US$4.6B | US$792.5M | US$3.8B | US$9.0B |
| Total debt | US$16.9B | US$16.2B | US$25.2B | US$33.6B | US$42.5B |
| Cash | US$3.8B | US$2.1B | US$2.8B | US$3.3B | US$7.3B |
Compound annual growth: revenue 23.2% · net income 38.7% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 43.9x | 62.0x | 26.4x |
| EV / EBITDA | 29.4x | 41.3x | 16.3x |
| Operating margin | 46.1% | — | 3.6% |
| Net margin | 31.9% | — | -0.0% |
| Debt / equity | 2.68 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Eli Lilly and Company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for n…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice